The Responsiveness of Breast Cancer Cells to Varied Levels of Vitamin B12, Cisplatin, and G-CSF
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26189086 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Volkan Aslan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Faculty of Medicine, Gazi University, 06560 Ankara, Türkiye. Hauptthemen laut MEDLINE: Cisplatin, Granulocyte Colony-Stimulating Factor, Vitamin B 12, Breast Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This study was supported by the Scientific Research Projects Coordination Unit of Gazi University (Project Code: TCD-2022-7970)., the Scientific Research Projects Coordination Unit of Gazi University.
Abstract (Originalsprache)
Supportive agents, such as vitamin B12 (cobalamin, B12) and granulocyte colony-stimulating factor (G-CSF), are widely used during chemotherapy; however, their direct effects on tumor biology are not well understood. We evaluated the impact of pharmacological B12 and G-CSF, alone or in combination with cisplatin, on hormone receptor-positive (MCF-7) and triple-negative (MDA-MB-231) breast cancer cells, conducting in vitro assays of cell viability, cytotoxicity, caspase activation, mitochondrial membrane potential, and cytolytic protein expression. Neither B12 nor G-CSF alone induced cytotoxicity; instead, both promoted proliferation in a dose- and time-dependent manner. When combined with cisplatin, they consistently attenuated drug-induced cytotoxicity, suppressed caspase-3/-8/-9 activation, preserved mitochondrial integrity, and reduced perforin/granzyme expression, exhibiting stronger effects in MCF-7 cells. G-CSF markedly increased proliferation (>130% at 50 ng/mL), while B12 modestly enhanced viability and mitigated cisplatin-induced damage, particularly in triple-negative cells. These findings indicate that B12 and G-CSF can impair cisplatin efficacy by blunting apoptotic signaling and mitochondrial injury in different breast cancer subtypes. These preclinical findings warrant prospective, biomarker-driven in vivo and clinical studies to delineate the clinical contexts in which B12 and G-CSF can be safely integrated into supportive care without compromising antitumor efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Faculty of Medicine, Gazi University, 06560 Ankara, Türkiye.
- Department of Medical Biology and Genetics, Faculty of Medicine, Gazi University, 06560 Ankara, Türkiye.
- Department of General Surgery, Faculty of Medicine, Gazi University, 06560 Ankara, Türkiye.
ORCID-Profile: Volkan Aslan, Osman Sütcüoglu
Förderung
- This study was supported by the Scientific Research Projects Coordination Unit of Gazi University (Project Code: TCD-2022-7970).
- the Scientific Research Projects Coordination Unit of Gazi University
Zitieren
APA
Aslan, V., Usta, D. D., Yar Sağlam, A. S., Özet, A., Sütcüoglu, O., Dikmen, K., & Özdemir, N. (2025). The Responsiveness of Breast Cancer Cells to Varied Levels of Vitamin B12, Cisplatin, and G-CSF. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26189086
Vancouver
Aslan V, Usta DD, Yar Sağlam AS, Özet A, Sütcüoglu O, Dikmen K, et al. The Responsiveness of Breast Cancer Cells to Varied Levels of Vitamin B12, Cisplatin, and G-CSF. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26189086
BibTeX
@article{Aslan2025,
author = {Aslan, Volkan and Usta, Duygu Deniz and Yar Sağlam, Atiye Seda and Özet, Ahmet and Sütcüoglu, Osman and Dikmen, Kürşat and Özdemir, Nuriye},
title = {The Responsiveness of Breast Cancer Cells to Varied Levels of Vitamin B12, Cisplatin, and G-CSF},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26189086}
}
EUVIMED